EPO and anemia (phenotype): Two of these were products of the new biotechnology industry: recombinant human growth hormone (r-HGH), marketed independently by Genentech and Eli Lilly, and approved for treatment of children with growth failure; and Amgen’s recombinant erythropoietin (r-EPO), used to treat anaemia associated with chronic renal failure.105